Literature data suggest that plasma amyloid beta (Aβ 1-40/2) peptides are elevated in populations at risk for Alzheimerʼs disease (AD) and progressively decline during the conversion from Mild Cognitive impairment to AD. At present, there is no consensus regarding the optimal methodology for conducting quantification of plasma Aβ 1-40 or Aβ 1-42. Further, there is insufficient evidence supporti...

Alzheimer's disease (AD) is a neurodegenerative disease exhibiting amyloid beta (Aβ) peptide accumulation as a key characteristic. Autophagy, which is dysregulated in AD, participates in the metabolism of Aβ. Unexpectedly, we recently found that autophagy, in addition to its degradative function, also mediates the secretion of Aβ. This finding adds Aβ to an increasing number of biomolecules, th...

Amyloid beta (Aβ) homeostasis in the brain is governed by its production and clearance mechanisms. An imbalance in this homeostasis results in pathological accumulations of cerebral Aβ, a characteristic of Alzheimer's disease (AD). While Aβ may be cleared by several physiological mechanisms, a major route of Aβ clearance is the vascular-mediated removal of Aβ from the brain across the blood-bra...

We addressed the question of whether injection of Amyloid beta (Aβ)(1-40) in the rat brain is associated with pathology in the hippocampus, and if genistein has any protective effect against the neuronal damage caused by Aβ(1-40). Genistein is a plant-derived compound with a structure similar to that of the female sex hormone estrogen and it was recently shown that pretreatment with a single do...

Amyloid precursor protein (APP) is cleaved by gamma-secretase to simultaneously generate amyloid beta (Aβ) and APP Intracellular Domain (AICD) peptides. Aβ plays a pivotal role in Alzheimer's disease (AD) pathogenesis but recent studies suggest that amyloid-independent mechanisms also contribute to the disease. We previously showed that AICD transgenic mice (AICD-Tg) exhibit AD-like features su...

Introduction: Alzheimer’s disease (AD) is a common progressive, neurodegenerative disorder with no preventive or curative therapy until now. Use of natural products as an important source of neuroprotective flavonoids against AD has been considered recently. In this study, the effect of Mespilus germanica leaves (MGL) flavonoids treatment on memory dysfunction and apoptosis in the amyloid beta ...

Halogenation of organic compounds plays diverse roles in biochemistry, including selective chemical modification of proteins and improved oral absorption/blood-brain barrier permeability of drug candidates. Moreover, halogenation of aromatic molecules greatly affects aromatic interaction-mediated self-assembly processes, including amyloid fibril formation. Perturbation of the aromatic interacti...

We propose the application of a new label-free optical technique based on photonic nanostructures to real-time monitor the amyloid-beta 1-42 (Aβ(1-42)) fibrillization, including the early stages of the aggregation process, which are related to the onset of the Alzheimer's Disease (AD). The aggregation of Aβ peptides into amyloid fibrils has commonly been associated with neuronal death, which cu...

Objective Recently developed 18F-labelled amyloid beta (Aβ) positron emission tomography (PET) tracers have demonstrated potentials to enable more prevalent application of amyloid imaging in the clinical setting. The aim of this study is to demonstrate cerebral retention of Aβ in cognitively normal older adults, by implementing voxel-based analysis on images acquired from 18F-Florbetaben amyloi...

Alzheimer’s disease (AD) is characterized clinically by a progressive decline in cognition, and histopathologically by the presence of senile plaques (consisting mainly of amyloid-β, Aβ) and neurofibrillary tangles in the brain, and the degeneration of basal forebrain cholinergic neurons. Aβ, a 39-43 amino acid long peptide, is derived by proteolytic processing from its precursor, the amyloid p...